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SUMMARY 
 
Glycosylceramides that activate CD1d-restricted invariant natural killer T (iNKT) cells have potential 
therapeutic applications for augmenting immune responses against cancer and infections. Previous studies 
using mouse models identified sphinganine variants of α-galactosylceramide as promising iNKT cell 
activators that stimulate cytokine responses with a strongly proinflammatory bias. However, the activities of 
sphinganine variants in mice have generally not translated well to studies of human iNKT cell responses. 
Here, we show that strongly proinflammatory and anti-tumor iNKT cell responses were achieved in mice by a 
variant of α-galactosylceramide that combines a sphinganine base with a hydrocinnamoyl ester on C6″ of the 
sugar. Importantly, the activities observed with this variant were largely preserved for human iNKT cell 
responses. Structural and in silico modeling studies provided a mechanistic basis for these findings and 
suggested basic principles for capturing useful properties of sphinganine analogs of synthetic iNKT cell 
activators in the design of immunotherapeutic agents. 
 
 
INTRODUCTION 
 
Invariant natural killer T (iNKT) cells are a subset of unconventional T cells that participate in both adaptive 
and innate immunity (Bendelac et al., 2007, Brennan et al., 2013). A major feature that sets them apart from 
conventional T cells, which recognize peptides presented by major histocompatibility complex (MHC) 
molecules, is their recognition of lipid-based antigens presented by the MHC class I-like CD1d protein 
(Rossjohn et al., 2012). Since the discovery over two decades ago that natural forms of α-galactosylceramide 
(α-GalCer) known as agelasphins and their synthetic analogs are potent stimulators of iNKT cell responses 
with anti-cancer activities (Kawano et al., 1997, Morita et al., 1995), there has been increasing interest in 
incorporating iNKT cell activators into strategies for immunotherapy and vaccination (Cerundolo et al., 
2009, Kharkwal et al., 2016). The first α-GalCer developed from systematic structure-activity relationship 
studies was KRN7000 (Fig  1A) (Kobayashi et al., 1995). In mouse models, KRN7000 also showed potent 
anti-tumor properties, as well as considerable promise for the treatment of infectious and autoimmune 
diseases (Cerundolo and Salio, 2007). 
 
Despite the potent immune activating properties of KRN7000, there has been relatively limited success to 
date in advancing it into clinical use. Small phase 1 trials in human cancer patients have shown, at best, 
limited evidence of clinical benefit (Nair and Dhodapkar, 2017), and there are features of the response to 
KRN7000 in vivo that may render it suboptimal for tumor immunotherapy and other potential applications (Yu 
and Porcelli, 2005). A major issue in this regard is the tendency for KRN7000 to elicit high levels of both T 
helper 1 (Th1) and Th2 associated cytokines, which may have directly conflicting activities leading to 
ineffective and unpredictable immune responses. This problem has been addressed through the 
development of structural analogs of KRN7000 that stimulate iNKT cell responses that are more biased 
toward purely Th1 or Th2 cytokine predominance (Laurent et al., 2014). In general, analogs that bias toward 
interferon-γ (IFNγ) and other Th1-type cytokines following iNKT cell activation have been associated with 
favorable therapeutic effects in mouse models of cancer and infectious diseases (Kopecky-Bromberg et al., 
2009, Schmieg et al., 2003), whereas Th2-biasing analogs may be more suitable for treatment of 
autoimmune or inflammatory conditions (Forestier et al., 2007, Miyamoto et al., 2001). Thus, it is well 
recognized that identifying ligands that selectively elicit Th1 or Th2 cytokines will likely be crucial for effective 
therapeutic applications of iNKT cell activation (Cerundolo and Salio, 2007, Laurent et al., 2014). 
 
The first Th1-biasing compound reported was α-C-GalCer (Fig  1A), which showed marked superiority to 
KRN7000 in mouse cancer and infection models (Kopecky-Bromberg et al., 2009, Schmieg et al., 2003). 
However, in studies using cell culture models of human iNKT cell responses, α-C-GalCer has been found to 
be only weakly stimulatory, suggesting that it may not be suitable for development as a human therapeutic 
(Li et al., 2009a, Li et al., 2009b, Venkataswamy et al., 2014). Another strongly Th1-biasing iNKT cell agonist 
that was previously identified is the aminodiol (sphinganine) analog (AH03-1 in Fig  1A) of KRN7000, which 
has activities similar to α-C-GalCer in mouse models (Arora et al., 2011). AH03-1 and other related 
sphinganine analogs have generally been found to be highly active in vivo in mice or in vitro with mouse cells 
(Brossay et al., 1998, Ndonye et al., 2005, Sidobre et al., 2004), although two previous studies found that 
they were not efficient activators in cell culture models of human iNKT cell responses (Brossay et al., 
1998, Dangerfield et al., 2012). Among the more recently reported Th1-biasing analogs of α-GalCer are 
those in which the sugar has been modified by C6″-substituted amides, carbamates, and ureas. Some, such 
as NU-α-GalCer and PyrC-α-GalCer (Fig  1A), show promising anti-tumor activity in mice and elicit a Th1-
biased response in studies using human iNKT cells in vitro (Aspeslagh et al., 2011, Aspeslagh et al., 2013). 
 
Considering the responses of selected C6″-substituted compounds in human cell lines and the strongly 
biased Th1 response elicited by the sphinganine-containing AH03-1, we have explored whether combining a 
C6″ substitution with a sphinganine variant of α-GalCer could provide useful synergistic effects. Herein we 
report studies on a α-GalCer analog, designated AH10-7, which incorporates a C6″ hydrocinnamoyl ester 
and lacks the C4′-OH of the sphingoid base. Using a combination of in vitro studies and in vivo analysis with 
wild-type and partially humanized mice, we found that the dual modifications in AH10-7 led to preservation of 
substantial potency in both mouse and human models of iNKT cell activation while maintaining the Th1-
biasing property of other sphinganine derivatives. Structural studies by X-ray crystallography and in 
silico modeling provided a mechanistic basis for the effect of the C6″ substitution on enhancing presentation 
of AH10-7 by human CD1d. Our results, along with another recently published study of combining C6″ 
substitutions with other Th1-biasing modifications (Guillaume et al., 2017), provide a rare example of two 
separate glycolipid modifications that synergize to create an analog of KRN7000 with potentially useful 
properties, suggesting a new approach to rational design of iNKT cell T cell receptor (TCR) ligands. 
 
 
RESULTS 
 
Synthesis and bioactivity of an α-GalCer derivative combining sphinganine and C6″ modifications 
To examine the impact of linking an aromatic group to the sugar C6″ in combination with removal of the 4′-
OH of the phytosphingosine chain, we synthesized the sphinganine-containing compound AH10-7 and for 
comparison its phytosphingosine congener AH15-1, as outlined in Fig  1B. Both glycolipids were prepared by 
the glycosylation of known protected forms 1 (Ndonye et al., 2005) and 2 (Kim et al., 2004) of their respective 
ceramides (Fig  1B). Thiophenyl-activated carbohydrate 3, used for both glycosylations, was prepared by 
esterification of a previously described, partially protected thiophenyl galactose (Bourgeaux and Combret, 
2000; Ziegler et al., 1999). The coupling reactions between 3 and 1 or 2 gave high α-selectivity, and the 
resultant α-GalCers were deprotected under standard conditions to give AH10-7 and AH15-1 (See Suppl 
Information). 
 
Initial assessment of bioactivity was done using cell culture with a mouse iNKT cell hybridoma (DN3A4-1.2) 
and bone marrow-derived dendritic cells (DCs) (Im et al., 2009). To assess presentation of the glycolipids by 
mouse (m) versus human (h) CD1d, we used bone marrow derived DCs from either wild type or human 
CD1d knock-in (hCD1d-KI) mice. The latter, in which the coding sequence of the mouse CD1D gene has 
been replaced by the orthologous human CD1D sequence, has been previously described as a partially 
humanized mouse model for the study of iNKT cell responses (Wen et al., 2015; Wen et al., 2013). 
Measurement of IL-2 release as an indicator of iNKT cell activation showed similar potency over a wide 
range of concentrations for KRN7000 and both sphinganine derivatives (AH03-1 and AH10-7, Fig  2A) when 
presented by mCD1d. In contrast, with hCD1d-expressing DCs, AH03-1 showed minimal ability to stimulate 
the mouse iNKT cell hybridoma, whereas AH10-7 retained partial activity relative to KRN7000. 
 
These findings with a canonical iNKT cell line expressing a single clonal antigen receptor (TCR) indicated 
that the addition of the C6″ hydrocinnamoyl group partially restored hCD1d presentation of a sphinganine 
derivative of KRN7000. To extend this to iNKT cells with more heterogeneous TCRs, we sorted iNKT cells 
from the spleens of both wild type and hCD1d-KI mice and fused these to thymoma line BW5147α−β− to 
generate polyclonal iNKT cell lines (Johnson et al., 2017). Similar to the results with the clonal mouse iNKT 
cell line, we found that a polyclonal iNKT cell line from wild type mice showed nearly equivalent responses to 
the three glycolipids when presented by mCD1d, while a marked reduction in responses was seen for AH03-
1 but not AH10-7 when presented by hCD1d (Fig  2B, left). A similar trend, although slightly less 
pronounced, was observed for a polyclonal iNKT cell line derived from hCD1d-KI mice (Fig  2B, right). 
 
We further investigated the differential presentation of AH10-7 and AH03-1 by hCD1d using fully human cell 
culture systems. Stimulation of human iNKT cell clones with the glycolipids in the presence of human 
monocyte-derived DCs or hCD1d-transfected HeLa cells showed a significant diminution of activity 
compared to KRN7000 with the sphinganine derivative AH03-1, which was partially reversed by the C6″ 
substitution in AH10-7 (Fig  2C). In addition, we analyzed proliferation and expansion of primary iNKT cells in 
human PBMC cultures from four normal blood donors, which showed a similarly enhanced activity of AH10-7 
compared to the minimal expansion and proliferation induced by AH03-1 (Fig  3). Taken together, these in 
vitro studies indicated that the 4′-OH group of the sphingoid base had an important influence on presentation 
of α-GalCer by hCD1d but not mCD1d, and that the defect in presentation of a sphinganine derivative by 
hCD1d could be significantly overcome by incorporation of the C6″ hydrocinnamoyl group in AH10-7. 
 
Cytokine biasing properties and in vivo activity of AH10-7 
Previous studies have attributed a strong Th1 type cytokine bias to the sphinganine derivative AH03-1 in 
mice and correlated this with its presentation by CD1d proteins that localized preferentially to lipid raft 
microdomains in the plasma membrane of antigen presenting cells (Arora et al., 2016; Arora et al., 2011). 
We tested whether AH10-7 preserved the lipid raft localization by measuring the detergent sensitivity to 
elution of α-GalCer-mCD1d complexes from the surface of dendritic cells using a previously described flow 
cytometry-based assay (Arora et al., 2011) (Fig  4A). As previously shown, complexes of CD1d with the Th1-
biasing sphinganine derivative AH03-1 showed greater resistance to detergent elution from the plasma 
membrane compared to KRN7000, consistent with strong localization to lipid raft microdomains. For 
comparison, the strongly Th2-biasing glycolipid α-GalCer C20:2 (Fig  1A) showed rapid and nearly complete 
elution from the plasma membrane. AH10-7 behaved similarly to AH03-1 in this assay, showing strong lipid 
raft localization of its presentation. This was attributable to its sphinganine modification, since a 
phytosphingosine variant of AH10-7 (AH15-1, Fig  1B) behaved no differently than KRN7000 in this assay 
(Fig  4A). 
 
The preferential lipid raft localization of CD1d-α-GalCer complexes formed with AH10-7 suggested that this 
compound was likely to stimulate a Th1 cytokine bias in vivo, such as that previously shown for α-C-GalCer 
and AH03-1 in mice (Arora et al., 2011; Im et al., 2009; Schmieg et al., 2003). Measurement of serum levels 
of IFNγ and IL-4 after glycolipid injection into mice showed a significant enhancement of IFNγ without 
increases in IL-4 for AH10-7 compared to KRN7000 (Fig  4B). In contrast, AH15-1 which retains the 4′-OH 
group in the sphingoid chain, produced levels of both cytokines that were similar to those elicited by 
KRN7000. The altered ratio of IFNγ to IL-4 stimulated by AH10-7 was consistent with a Th1-biasing effect for 
this glycolipid that was significantly augmented compared to KRN7000 or AH15-1, although less pronounced 
than with AH03-1. Given the association of Th1-biasing properties with improved anti-cancer effects in mice 
(Schmieg et al., 2003; Venkataswamy and Porcelli, 2010), we tested the impact of AH10-7 compared to 
KRN7000 in the mouse B16-F10 melanoma model of metastatic cancer (Wen et al., 2013). This revealed 
strong antitumor activity of AH10-7 in both wild type and hCD1d-KI mice (Fig  4C), which was at least as 
great as for KRN7000 in this model. 
 
Structural analysis of the CD1d-AH10-7 complex and its molecular interactions with the iNKT TCR 
In order to gain structural insights into the molecular recognition of AH10-7 in comparison to KRN7000, we 
generated complexes in vitro of mCD1d loaded with these glycolipids and co-crystallized them with the 
2C12 iNKT cell T (Brennan et al., 2017; Pellicci et al., 2009; Wang et al., 2010) We used X-ray 
crystallography to determine the 3-dimensional structures of these ternary complexes to 3.2 Å resolution for 
AH10-7 and 2.6 Å for KRN7000 (Fig  5A, and Suppl Table 1). In both complexes, the electron density at the 
molecular interface between the mCD1d-glycolipid complexes and the 2C12 iNKT TCR was unambiguous. 
Most notably, distinct electron density corresponding to the in vitro loaded glycolipid antigens emerged from 
within the A′- and F′-portals of mCD1d and protruded out from the antigen binding cleft (Fig  5A and Suppl 
Fig  S1). 
 
The overall docking mode adopted by the 2C12 iNKT TCR to recognize mCD1d presenting KRN7000 and 
AH10-7 was conserved and was similar to the one previously observed in other crystal structures of iNKT 
TCR-CD1d-α-GalCer ternary complexes (Girardi et al., 2011; Rossjohn et al., 2012) (Fig  5B, and Suppl Fig  
S2). In both complexes, the 2C12 iNKT TCR adopted a parallel docking mode (docking angle of ~15°) over 
the F′-pocket of mCD1d. Upon 2C12 iNKT TCR ligation, the total buried surface area (BSA) of the TCR at 
the interface in both ternary complexes was ~800 Å2. The TCR α-chain contributed the most to the BSA 
(60% of total), and this was mainly through the CDR3α (44% of BSA). Here, the CDR3α bridged the α1- and 
α2-helices of mCD1d, with Asp94α and Arg95α hydrogen bonded to Arg79 and Asp80 (Fig  5B, left). The 
contribution of the TCR β-chain to the binding interface was more limited and was evenly shared mainly by 
the CDR2β, CDR3β and two framework residues (Tyr48β and Glu56β) (Fig  5B, right), each accounting for a 
10-15% BSA (Suppl Fig  S2). 
 
The distinct electron density not accounted for by polypeptide residues in the mCD1d-binding groove 
enabled us to model unambiguously AH10-7 and KRN7000 in both ternary complexes (Fig  5C, and Suppl 
Fig  S1). For both glycolipids, the hydrophobic N-acyl and sphingoid base chains were positioned deep within 
the A′- and F′-pockets of mCD1d, respectively, whereas the galactose polar moiety largely protruded out of 
the binding groove to interact with the TCR. Although the sphinganine of AH10-7 and phytosphingosine of 
KRN7000 adopted similar positions within the F′-pockets, we noted that the 4′-OH in the phytosphingosine 
chain enabled an additional hydrogen bond to Asp80 of mCD1d (Fig  5B). The static crystal structures did 
not detect rearrangement of the overall positioning of the glycolipid or significant impact on the mCD1d 
protein structure as a result of the presence or absence of this additional bond. However, as indicated by 
modeling studies (see below), the impact of removing the 4′-OH may be greater in hCD1d, potentially 
contributing to the apparent reduction in human iNKT cell responses promoted by AH03-1. 
 
The interactions of the 2C12 iNKT TCR with KRN7000 and AH10-7 bound in mCD1d were exclusively 
mediated by the TCR α-chain. In both ternary complexes, the galactose was located in a similar position and 
interacted exclusively with the CDR1α and CDR3α loops, with the C2″ and C3″ hydroxyl groups of the sugar 
forming hydrogen bonds with residues Arg95α and Asn30α, respectively (Fig  5C). It was noteworthy that the 
hydrocinnamoyl ester moiety of AH10-7 was positioned over the A′-pocket of mCD1d between Met69 and 
Met162, and interacted with Thr159 via van der Waals contacts. This pointed to a role for the C6″ 
substitution in strengthening the binding of AH10-7 to mCD1d, and stabilizing the position of the galactosyl 
head group for TCR recognition. 
 
To directly assess the binding affinity of the iNKT cell TCR to the mCD1d protein loaded with AH10-7 versus 
KRN7000, we analyzed binding by surface plasmon resonance using the same soluble TCR and mCD1d 
proteins used to generate the crystal structures of the ternary complexes (Fig  6A). Similar binding affinities 
of the TCR were observed for both AH10-7 and KRN7000 loaded mCD1d complexes (Kd ~100-110 nM), 
which was consistent with the close superposition of the galactose ring and other components of the TCR 
docking site in the crystal structures (Fig  6B). Comparison of AH10-7 with other C6″-substituted α-GalCer 
derivatives previously reported to show high levels of iNKT cell stimulatory activity indicated that all of these 
preserved a similar positioning of the galactose ring ((Aspeslagh et al., 2013) and Fig  6C), underscoring the 
importance of this feature in maintaining TCR binding affinity. 
 
In silico modeling and computational analysis of AH10-7 interactions 
The crystal structure of the 2C12 TCR-mCD1d-AH10-7 ternary complex provided an opportunity to use 
molecular modeling to further explore how the sphingoid base and sugar modifications synergize to generate 
the observed effects of AH10-7 on iNKT cell activation. We used grid-based ligand docking simulations to 
examine the interactions of similar ligands with and without the 4′-OH (KRN7000 and AH03-1) and the C6″ 
modification (AH15-1 and AH10-7). As a validation of this approach, we showed that the simulated binding 
pose of AH10-7 reproduced well the 2C12 TCR-mCD1d-AH10-7 ternary complex structure obtained by X-ray 
crystallography (Fig  7A). Docking also predicted that this ligand and its phytosphingosine congener AH15-1 
adopt a similar binding mode in complexes with hCD1d and the iNKT TCR (Suppl Fig  3). As in the 
experimentally determined structure (Fig  5), the most favored docking poses modeled for AH10-7 in the 
ternary mouse complex showed that Lys65, His68, and Met162 formed the sides, and Met69 the floor of a 
cleft on mouse CD1d above the A′-pocket to accommodate the hydrocinnamoyl substituent (Fig  7A). This 
cleft provides a hydrophobic shelter for the hydrocinnamoyl group that enables π-cation and π-π interactions 
with the side chain ammonium of mCD1d-Lys65 and imidazole of mCD1d-His68. By contrast, the favored 
poses of AH10-7 and AH15-1 modeled in the human ternary complex interdigitated the phenyl of the 
hydrocinnamoyl group between hCD1d-His68 and hCD1d-Trp153 to realize π-π stacking interactions with 
both of these residues (Fig  7B, and Suppl Fig  3). 
 
The in silico docking procedure provided structures from which binding energies could be calculated using a 
hybrid quantum mechanics/molecular mechanics (QM/MM) protocol (Duff Jr et al., 2011). The computed 
binding energies (Fig  7E) correlated with experimental bioactivity trends (Fig s 2 and and 3).3). Consistent 
with the observed trends in biological potencies, AH03-1 was found to have a less favorable binding energy 
relative to KRN7000 in the human versus mouse ternary complex (Fig  7E). Specifically, the sphingoid base 
in AH03-1 undergoes a displacement due to the absence of the 4′-OH that results in a net reduction of 
stabilizing van der Waals contacts with Tyr73 from CD1d. In contrast, the glycolipids with carbohydrate 
modifications (AH10-7 and AH15-1) were predicted to have more favorable binding in either the human or 
mouse system, suggesting that functionally relevant contacts realized through carbohydrate modification 
compensated for the lost interactions of the sphingoid base 4′-OH. In this manner, specific interactions 
established by the C6″-hydrocinnamoyl moiety improved binding energetics and correlated with the 
increased potency of AH10-7 for hCD1d presentation. 
 
 
DISCUSSION 
 
Sphinganine derivatives were identified by us and others in previous studies as attractive alternatives to 
phytosphingosine-containing α-glycosylceramides as iNKT cell activators (Lacone et al., 2009; Ndonye et al., 
2005). Significantly, sphinganine derivative AH03-1 is one of relatively few analogues known to induce a 
strongly Th1 cytokine biased response in mice (Arora et al., 2011), a property that correlates with improved 
anti-cancer and adjuvant effects (Arora et al., 2016; Schmieg et al., 2003). However, at least two previous 
studies indicated that sphinganine derivatives of KRN7000 may be relatively ineffective in models of 
human iNKT cell activation (Brossay et al., 1998; Dangerfield et al., 2012), questioning their suitability for 
further development as therapeutic agents. Given several reports showing enhancement of iNKT cell 
activation and anti-tumor activity in mice by addition of aromatic ring-containing groups to the C6″ position of 
the galactose of KRN7000 (Aspeslagh et al., 2011; Aspeslagh et al., 2013), we undertook the current study 
to examine the impact of a relevant C6″ substitution on improving hCD1d presentation of the sphinganine 
variant (AH03-1) of KRN7000. Our results using several in vitro models showed that the novel compound, 
AH10-7, which combined a sphinganine base with a C6″‐hydrocinnamoyl moiety, had the anticipated effect 
of enhancing iNKT cell activation when presented by hCD1d. In addition, we found that AH10-7 retained the 
strong bias toward presentation by CD1d molecules localized to plasma membrane lipid rafts. This is a 
feature consistently found for glycolipids that require cellular uptake for intracellular loading onto CD1d (Im et 
al., 2009), and it correlates strongly with the tendency to induce a proinflammatory Th1 cytokine bias (Arora 
et al., 2016; Arora et al., 2011). Indeed, we found that AH10-7 induced a significant increase in the systemic 
levels of IFNγ compared to IL-4 after injection into mice, consistent with preservation of lipid raft dependent 
presentation of this compound in vivo. 
 
Our analysis also took advantage of a hCD1d KI mouse model, which more faithfully replicates many of the 
features of human iNKT cell responses in comparison to standard wild type mice (Venkataswamy et al., 
2014; Wen et al., 2015; Wen et al., 2013). This mouse strain was generated by replacing the mouse genomic 
segment containing the exons encoding mCD1d with the homologous human genomic sequence (Wen et al., 
2013). Expression of hCD1d in tissues of these mice is similar to its physiologically normal pattern, and they 
develop a population of endogenous iNKT cells that closely mirrors the numbers, phenotype and functions of 
these cells in humans. The use of iNKT cell hybridomas and primary bone marrow-derived DCs from these 
mice allowed us to acquire further support for the importance of the 4′-OH for effective responses to α‐
GalCer in the context of hCD1d presentation. Most notably, AH10-7 was at least as active as KRN7000 for 
inducing antitumor responses against experimental metastases of the B16-F10 melanoma line in both wild 
type and hCD1d-KI mice, suggesting that the pairing of structural modifications used in the design of this 
compound may be a promising path for development of human therapeutics. 
 
A variety of structural and modeling analyses were employed to better understand the molecular basis for the 
effects of the two modifications to the α‐GalCer structure. These studies revealed that, similar to the 
previously described structure of other C6″-substituted forms of α-GalCer bound to CD1d (Aspeslagh et al., 
2011; Aspeslagh et al., 2013), the aromatic group and its linker to the galactose formed contacts that held it 
close to the surface of CD1d. This most likely stabilized the position of the galactose of the bound AH10-7, 
which was oriented almost identically to the analogous structure with KRN7000 (Fig  6B, Suppl Fig  S1). The 
complexes of mCD1d with either of these glycolipids bound had almost identical affinities for at least one 
mouse iNKT cell TCR, as shown using a soluble form of the TCR in surface plasmon resonance studies (Fig 
s 6A). This is consistent with the similar potency of KRN7000 and AH10-7 for activation of iNKT T cells with 
presentation by mCD1d, as observed experimentally (Fig  2). 
 
A plausible explanation for the importance of the 4′-OH group for human but not mouse CD1d presentation 
was provided by our modeling studies. These strongly suggested that the 4′-OH group is involved in 
stabilizing or adjusting the conformation of human but not mouse CD1d after binding α-GalCer. Interestingly, 
a marked difference in the sensitivity of human versus mouse CD1d presentation was also noted in previous 
studies of a truncated phytosphingosine variant of α-GalCer (Im et al., 2009), and structural analyses 
indicated that this was due to the human protein being intrinsically more sensitive to variations in the lipid 
chain occupying its F′ pocket (McCarthy et al., 2007). Based on our structural studies and modeling analysis, 
we propose that AH10-7 overcomes this inherent sensitivity of hCD1d to the sphingoid base structure and 
maintains the correct orientation of the galactose for TCR recognition through interactions of the 6″-
hydrocinnamoyl group with the surface of hCD1d. As indicated by our molecular modeling and docking 
analyses, the interactions of the C6″-hydrocinnamoyl moiety could account for the improved binding 
energetics predicted by docking (Fig  7E), and potentially explain the increased potency of AH10-7 despite 
the interactions lost from the absence of the sphingoid base 4′-OH. Given these structural insights, 
substitution of the phenyl terminus of the C6″-hydrocinnamoyl substituent with electron withdrawing groups 
may be a promising direction for future syntheses, since this should favor π-π stacking with the electron-rich 
His68 residue of hCD1d. Further studies along these lines should confirm the usefulness of our docking-
QM/MM methodology as an adjunct to other established methods for determining the structure-activity 
relationship of CD1d-presented ligands, and facilitate the development of effective iNKT cell activators for 
translation to clinical applications. 
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 
 
Animals 
C57BL/6 mice were purchased from Jackson Laboratory, and hCD1dKI mice were bred and maintained in 
the animal facilities of the Albert Einstein College of Medicine and the University of Southern California Keck 
School of Medicine. Animals were maintained according to the guidelines of the Association for Assessment 
and Accreditation of Laboratory Animal Care. Female mice between 6-8 weeks of age were used for all 
studies, and were housed under standard specific pathogen-free conditions. Animals were randomly 
assigned to experimental groups. Influence of sex or gender on the results of the experiments in this study 
have not been assessed. All studies involving mice were specifically approved by the Institutional Animal 
Care and Use Committees (IACUCs) of the Albert Einstein College of Medicine and the University of 
Southern California Keck School of Medicine. 
 
Human Subjects 
Adult peripheral human blood samples were obtained from the Australian Red Cross Blood Service under 
agreement number 13-04VIC-07. Three female donors (ages 16, 35 and 74 years) and one male donor (age 
68 years) were studied. Influence of sex or gender on the results of the experiments in this study have not 
been assessed. Informed consent for blood donation was obtained from all subjects. 
 
Cell Lines and Primary Cell Cultures 
The mouse iNKT hybridoma DN3A4-1.2 was obtained from Dr. Mitchell Kronenberg (La Jolla Institute for 
Allergy and Immunology, San Diego, CA). Hybridoma lines from female wild type or human CD1d knock-in 
mice were produced by fusion of purified splenic iNKT cells with mouse thymoma line BW5147α-β- using 
standard methods as previously described (Johnson et al., 2017). BMDCs from 6–8 week old female 
C57BL/6 mice (Jackson Laboratories) and from hCD1dKI mice bred in our facilities were generated and 
cultured as described previously (Arora et al., 2014). Human iNKT clones HDD3 and HDD5 were established 
from PBMCs of anonymous normal human donors as described, and were cultured at 37°C in a 5% 
CO2 incubator in RPMI-1640 medium with 10% human serum, recombinant human IL-2 and IL-7 (Bricard et 
al., 2010). The JAWS II cell line (derived from C57BL/6.p53−/− mice) was obtained from the American Type 
Culture Collection (ATCC) and was cultured at 37°C in a 5% CO2 incubator in α-MEM medium 
supplemented with 20% fetal calf serum (Atlanta Biologicals), 10 mM HEPES, 50 μM β-mercaptoethanol, 50 
μg/ml gentamicin, 100 ng/ml GM-CSF (Peprotech), 0.1 mM of nonessential amino acids (NEAA) and 
essential amino acids (EAA). The B16-F10 mouse melanoma cell line was obtained from the ATCC and 
maintained as a cryopreserved stock expanded by three passages. The identities of cell lines were not 
validated for this study. 
 
For in vitro proliferation and iNKT cell expansion assays, human peripheral blood mononuclear cells 
(PBMCs) were labelled with 2 uM carboxyfluorescein diacetate succinimidyl ester (CFSE) at 37°C for 10 
minutes. Labelled cells were then cultured in culture media with graded doses of glycolipid antigens for 7 
days in the presence of 50 U/ml human IL-2. Cultures were kept at 37°C in an incubator containing 5% CO2. 
Cells were harvested at the end of culture, labelled by staining with fluorescently labelled anti-CD3 mAb and 
α-GalCer loaded hCD1d tetramers, and analyzed for proliferating cells through generational dye divisions via 
flow cytometry. 
 
 
 
 
 
METHOD DETAILS 
 
Glycolipid Synthesis 
KRN7000 is commercially available (Avanti Polar Lipids). The syntheses of AH03-1 and DB03-4 have been 
previously reported (Ndonye et al., 2005; Yu et al., 2005). Synthetic methods and compound characterization 
for glycolipids AH10-7 and AH15-1 can be found in the Suppl Experimental Procedures. All chemicals, 
solvents and deuterated solvents were purchased from Sigma-Aldrich, Alfa-Aesar, Oakwood Chemicals or 
Fisher Scientific and used as received unless noted. Methylene chloride (DCM) was dried over CaH2. 
Deuterated chloroform (CDCl3) was dried over activated 4 Å molecular sieves. All reactions, unless 
specified, were conducted under an atmosphere of N2 in glassware that had been oven or flame dried. 1H 
NMR spectra were recorded at 400 MHz and/or at 500 MHz and calibrated to the residual CHCl3 peak at 
7.27 ppm. 13C NMR spectra were recorded at 100 MHz and/or at 125 MHz and calibrated to the 
CDCl3 peak at 77.23 ppm. Chemical shifts are reported in units of parts per million (ppm). Infrared (IR) 
spectra were recorded on an FT-IR spectrophotometer and are reported in cm−1. High-resolution mass 
spectra were obtained on an AccuTOF instrument at the University of Connecticut. Specific rotations 
[α]D were obtained on a JASCO P-2000 polarimeter, using the sodium D-line as a source, and the 
concentration (c) is expressed in g per 100 mL. Flash chromatography was performed on silica gel, 40 
microns, 32-63 flash silica. Thin layer chromatography was performed on silica gel (silica gel 60 F254) glass 
plates, and the compounds were visualized by UV and/or 5% phosphomolybdic acid in ethanol. 
 
Reconstitution of Glycolipids for In Vitro and In Vivo Administration 
For in vitro assays, glycolipid stock solutions were prepared at 100 μM in DMSO (Sigma). Immediately 
before use, these stocks were heated to 70°C, sonicated for 5 min and then diluted to 1 μM in pre-warmed 
(37°C) culture medium (RPMI-1640 with 10% FCS). This stock was further diluted with culture medium 
immediately before adding to cell cultures to give the desired final glycolipid concentrations ranging from 
0.01 - 1000 nM, and a final DMSO concentration of ≤ 1%. For in vivo injection into mice, glycolipids were first 
dissolved to 20 mM in DMSO, and then further diluted to 200 μM using PBS + 0.5% Tween-20. This solution 
was diluted 1:10 with prewarmed (80°C) PBS immediately before injection of mice. Injection of 200 μl 
delivered 4 nmol of glycolipid in a vehicle with final composition of PBS + 0.1% DMSO + 0.05% Tween-20. 
 
CD1d Tetramer Preparation 
The cDNA sequences encoding human β2-microglobulin (encoding amino acids IQRTP to RDMGS) and the 
extracellular domains of human CD1d (encoding amino acids VPQRL to VLYWGS and C-terminal BirA and 
hexahistidine tags (amino sequence GLNDIFEAQKIEWHEHHHHHH)) were cloned into the expression 
vector pHLsec and transfected into mammalian HEK-293S.GnTI cells. The expressed soluble hCD1d/β2M 
protein complexes were purified from the culture supernatant using Nickel agarose affinity columns and 
biotinylated using BirA-specific biotin ligase enzyme. Biotinylated CD1d was loaded with α-GalCer PBS-44 
provided by Paul Savage (Brigham Young University) and converted to fluorescent tetramers by the addition 
of phycoerythrin (PE)-conjugated streptavidin (BD Biosciences). 
 
In Vitro and in Vivo Activation of iNKT Cells 
Mouse iNKT hybridoma lines were stimulated using standard conditions with mouse BMDCs as APCs, and 
supernatants were harvested after 18 h for determination of levels of IL-2 by capture ELISA (Im et al., 2009). 
Human iNKT cell lines were co-cultured in 96 well plates at 2 × 104 cells/well with APCs (2 × 104/well 
hCD1d-transfected HeLa cells or monocyte-derived DCs) in 100 μL of RPMI-1640 supplemented with 10% 
human serum, 30 U/mL IL-2 and 10 ng/mL IL-7 at 37°C (Spada et al., 2000). Glycolipid antigens were added 
at concentrations ranging from 0.1 – 1000 nM. Supernatants were harvested after 18 h of culture, and 
concentrations of human IFNγ were measured by capture ELISA as described (Bricard et al., 2010; Im et al., 
2009). For in vivo stimulation of iNKT cells, C57BL/6 and hCD1dKI mice were injected i.v. via the retro-orbital 
plexus with 4 nmol of glyclolipids. Mice were bled 2 h and 24 h later, and serum samples were stored at -
80°C before cytokine measurement by cytometric bead array (BD Biosciences) according to instructions 
provided with the assay kit. 
 
Lipid Raft Localization of CD1d/Glycolipid Complexes 
The method used for estimating lipid raft localization by detergent sensitivity has been described previously 
in detail (Arora et al., 2011). Briefly, JAWS II cells were seeded at a density of 2.5 ×105 cells per well in 100 
μl culture media in flat bottom 96 well plates. Glycolipids were added to a final concentration of 200 nM. As 
an inert vehicle control, the cells were cultured in medium containing only 0.02% DMSO. After 16 h of 
culture, the cells were detached, washed 3 times and resuspended in 50 μl of FACS buffer (PBS + 1% FCS 
+ 0.05% sodium azide) and stained with 5 μg/ml of the mCD1d/α-GalCer complex-specific mAb L363, which 
was produced and conjugated with Alexa Fluor 647 as previously reported (Yu et al., 2007). For estimation of 
lipid raft residency, the FACS analysis was performed in a kinetic mode. Triton X-100 was added to a final 
concentration of 0.06%, and fluorescence intensities were monitored before and after the addition of Triton 
X-100 for 30s. Data were collected as flow cytometry standard (FCS) files and analyzed using FlowJo 
software (Tree Star Inc.). MFI values at time 0 (prior to addition of Tx-100) were normalized to 100%, and the 
relative decrease in MFI values for different agonists after addition of Tx-100 were compared. 
 
Determination of B16-F10 Melanoma Lung Metastases 
B16-F10 metastasis assays were performed as previously described (Schmieg et al., 2003; Wen et al., 
2013). Briefly, C57BL/6 mice and hCD1dKI mice (6-8 weeks old, female) were injected i.v. with 4 × 105 B16-
F10 melanoma cells in 200 μl 2-3 days after administration of 4 nmol i.v. of KRN7000 or AH10-7. Two weeks 
after challenge, mice were sacrificed, lungs removed, and the numbers of melanized nodules per lung visible 
under low magnification (10×) were counted. 
 
Expression and Purification of Mouse CD1d and 2C12 αβ TCR Proteins 
Mouse CD1d associated with β2-microglobulin (β2m) was expressed and purified as reported previously 
(Pellicci et al., 2009). In brief, the mouse CD1d/β2m construct harboring BirA and Histidine affinity tags was 
cloned into the pFastBac™ plasmid. The recombinant Bacmid was then amplified in SF9 insect cells and 
subsequently used to transfect HighFive™ (Hi5) insect cells. The secreted mouse protein was purified by Ni-
NTA affinity chromatography (HisPur™-Thermo Scientifics), followed by size exclusion chromatography. The 
2C12 αβ TCR construct was kindly provided by Daniel G. Pellicci (University of Melbourne, Australia), and 
the 2C12 TCR protein was expressed in E. coli and purified as inclusion bodies. The refolding and 
purification procedures for the soluble 2C12 TCR were based on previously described methods (Garboczi et 
al., 1996). 
 
Glycolipid Loading of mCD1d and Purification of Ternary Complexes 
Glycolipids solutions of AH10-7 and KRN7000 at 1 mg/ml in PBS with 0.5% tyloxapol and 2.5% DMSO were 
sonicated for 20 min and immediately transferred to a 60°C water bath for 1 min. The lipids were then added 
directly to mCD1d at molar ratios ranging from 3:1 to 10:1 and incubated at room temperature for 15 h. The 
loaded proteins were then purified by anion exchange chromatography (MonoQ). The formation of the 2C12 
TCR-mCD1d-Ag complex was achieved by mixing the desired glycolipid-loaded mCD1d and the 2C12 TCR 
at a 1:1 molar ratio in a buffer containing 10 mM Tris-pH 8.0, 150 mM NaCl and incubated on ice for 2 h. The 
ternary complex was then purified by size exclusion chromatography using a Superdex 200 gel filtration 
column (GE Healthcare). 
 
Surface Plasmon Resonance 
The affinities between the 2C12 TCR and mCD1d loaded with AH10-7 or KRN7000 were measured by 
surface plasmon resonance (SPR) using a Biacore3000 (GE Healthcare). The glycolipid-loaded mCD1d was 
biotinylated and passed over a streptavidin (SA)-coated chip in HBS buffer (150 mM NaCl, 10 mM HEPES, 
pH 7.4) to capture ~3000 response units (RU) of biotinylated protein to the chip surface. A series of 
concentrations of the 2C12 TCR ranging from 0 to 50 μM in HBS buffer at 25°C were used to examine the 
affinity for mCD1d-glycolipid complexes. The specific response was determined by subtracting the response 
of a flow cell coated by streptavidin or by mCD1d loaded with endogenous lipids. The BIAevaluation 3.1 
software (Biacore AB) was used to estimate the steady-state Kd values, and the Prism program was used for 
statistical analysis, curve fitting and graphic presentation. 
 
X-ray Crystallography 
Crystals of the 2C12 TCR-mCD1d-AH10-7 and 2C12 TCR-mCD1d-KRN7000 ternary complexes were grown 
in hanging drops containing 5 mg/ml protein at 4°C in 18-20% PEG 3350, 8% Tacsimate pH 5.0 and 0.5% 
dioxane. The crystals were flash-frozen and data were collected at the Australian Synchrotron (MX2 
beamline). The data were processed with the program iMOSFLM and were scaled with SCALA from the 
CCP4 suite of programs (Winn et al., 2011). Molecular replacement was carried out with the program 
PHASER (McCoy, 2007; McCoy et al., 2007) and using the mouse CD1d and the αβ TCR from the ternary 
complex structure (PDB code: 3QUZ) as independent search ensembles. Iterative model improvement and 
refinement cycles were performed with the programs COOT (Emsley et al., 2010) and BUSTER 2.10 
(Bricogne et al., 2017), respectively. The quality of the structures was confirmed at the Research 
Collaboratory for Structural Bioinformatics Protein Data Bank Data Validation and Deposition Services 
website. Visual representations were generated using MacPyMOL (PyMOL Molecular Graphics System, 
Version 2.0 Schrödinger, LLC. . 
 
Computational Methods 
For the docking experiments, the mCD1d-TCR and hCD1d-TCR complexes from PDB files 6BNL and 3VWK, 
respectively, were prepared (e.g., H atoms added, protonation and tautomeric states assigned, and H-bond 
donor/acceptor groups reoriented) with the Protein Preparation application in Maestro version 10.6.014 
(Sastry et al., 2013). In order to have all-atom models of the binding site, the unresolved side chain of CD1d-
Lys65 in PDB 6BNL was reconstructed by superimposing the backbone of CD1d from a previous crystal 
structure (PDB 4IRJ) with the similarly bound C6″-modified α-GalCer AH10-7. Semi-flexible docking was 
performed with standard precision Glide (Halgren et al., 2004). The galactose and glycosidic linkage were 
treated flexibly, while torsions along the sphingoid base and fatty acid chains were fixed to the 
crystallographic values. Because sphinganine- and phytosphingosine-containing ceramides experimentally 
have different chain conformations in the CD1d binding groove, docked ligands were derived from CD1d-
TCR crystal structures loaded with each of these types of ligands. 
 
For docking into mCD1d-TCR, AH10-7 was taken from PDB 6BNL, and AH03-1 was prepared by replacing 
the C6″-hydrocinnamoyl substituent of AH10-7 with a hydroxyl. The phytosphingosine-containing AH15-1 
was derived from Nu-α-GalCer, because PDB 3QUZ is the highest resolution crystal structure of a C6″-
modified phytosphingosine-based ligand available. KRN7000 was built from AH15-1 by replacement of the 
C6″-substituent in the same manner that AH03-1 was prepared from AH10-7. For docking into hCD1d-TCR, 
AH03-1 was prepared from the 4′,4″-dideoxy analogue of KRN7000 present in the PDB 3VWK crystal 
structure by adding the C4″-OH of the galactose. AH10-7 was then prepared by replacing the C6″-OH with 
the hydrocinnamoyl group. KRN7000 was taken from PDB 2PO6, and as with AH10-7, AH15-1 was prepared 
by substituting the hydrocinnamoyl group for the C6″-OH. Eight rotamers for each ligand were generated by 
varying the orientation of the C3″- and C4″-OH groups. These rotamers were docked, and the top ten poses 
for each submitted structure were conformationally clustered into distinct poses. 
 
Using the highest ranked docking poses from Glide, we performed QM/MM calculations of all complexes 
containing mouse or human CD1d with optimization of only the glycolipid ligands (Duff Jr et al., 2011). 
B3LYP/6-31g* was used for the QM region (ligands) and the OPLS-AA force field for the rest of the protein 
as implemented in Qsite (Schrodinger Inc.) (Murphy et al., 2000). Binding energies were modeled by 
subtracting from the QM/MM energy the MM energy of the apo-protein (CD1d-TCR) and the minimized 
energy of the ligand in octanol. The Poisson-Boltzmann method was used for implicit solvent calculations 
(Tannor et al., 1994). 
 
 
QUANTIFICATION AND STATISTICAL ANALYSIS 
 
Data are shown as mean values with error bars representing one standard error (SE). Levels of significance 
were P < 0.05 (*), P < 0.01 (**), P < 0.001 (***), P < 0.0001 (****), Statistical analyses were done using 
GraphPad Prism software. Data with multiple groups were analyzed for overall significance using one-way 
ANOVA, and level of significance for pairwise comparisons of selected groups was calculated using Dunnet 
post-test. Group sizes (n) for individual experiments are defined in the Fig  legends. 
 
 
DATA AND SOFTWARE AVAILABILITY 
 
The structures of the NKT 2C12 TCR-CD1d-KRN7000 and NKT 2C12 TCR-CD1d-AH10-7 ternary 
complexes were deposited in the RCSB Protein Data Bank (PDB) under the accession codes 6BNK and 
6BNL, respectively. 
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FIG 1 
 
 
Structures and synthesis of α-GalCer derivatives       
A) Structures of KRN7000 (with 4′ and 6″ positions noted) and some examples of cytokine biasing derivatives. 
B) Structure and synthetic strategy for novel C6″ modified α-GalCer derivatives AH10-7 and AH15-1. 
 
 
  
FIG 2 
 
 
 
In vitro iNKT cell activation by 4′-deoxyphytosphingosine variants of α‐GalCer 
A) Activation of mouse iNKT cell hybridoma DNA3.4-1.2 by KRN7000 or 4′-deoxy variants AH03-1 and 
AH10-7. The indicated concentrations of glycolipids were added to co-cultures of DNA3.4-1.2 cells with 
BMDCs from either wild type C57BL/6 mice (top, mCD1d) or from hCD1d-KI mice (bottom, hCD1d). 
Activation of iNKT hybridoma cells was determined by measurement of IL-2 levels in culture supernatants by 
ELISA after 18 h of culture. Symbols show means and error bars represent ± 1 SE for triplicate values, and 
results shown are representative of five separate experiments. 
B) Polyclonal iNKT cell hybridoma lines derived from wild type C57BL/6 mice (left, B6 iNKT) or from hCD1d 
KI mice (right, KI iNKT) were co-cultured with either wild type BMDCs (top, filled bars) or hCD1d-KI 
BMDCs (bottom, hatched bars) plus 100 nM of the indicated glycolipids. Activation of iNKT hybridoma cells 
was determined by measurement of IL-2 secretion at 18 h. Results shown are means ± 1 SE for duplicate 
samples, and are representative for two separate experiments. 
C) Left: responses of human iNKT cell clone HDD5 co-cultured with human monocyte-derived dendritic cells 
(hMDDC) and 100 nM of the indicated glycolipids. Supernatants were harvested after 24 h of culture for 
measurement of IFNγ levels. Right: responses of human iNKT cell clone HDD3 to 100 nM of the indicated 
glycolipids presented by HeLa cells transfected with hCD1d. Results shown are means ± 1SE for triplicate 
samples, and are representative of 3 separate experiments. 
Significant differences compared to response to KRN7000 in B and C are indicated by asterisks, *P < 0.05, 
**P < 0.01, ***P < 0.001 (ANOVA with Dunnet post-test for multiple comparisons) 
 
 
  
FIG 3 
 
 
Expansion and proliferation of human peripheral blood iNKT cells 
A) CFSE-labelled human peripheral mononuclear cells (PBMCs) were pulsed with respective lipids and 
cultured for 7 days in the presence of 50 U/ml of human IL‐2. Representative FACS plots from one donor show 
α-GalCer loaded CD1d tetramer positive iNKT cells (red ovals) and tetramer negative CD3+ T cells (blue 
rectangular regions), followed by the histograms of cells that have proliferated based on CFSE dilution. Blue 
histograms are tetramer negative CD3+ T cells, and red histograms are tetramer positive iNKT cells. 
B) Graphs depicts the fold expansion of iNKT cell percentages at the end of culture relative to the unstimulated 
sample (left), and the percentage of iNKT cells that have proliferated based on CFSE dilution (right). Each 
scatter point represents an independent donor sample, and bars are mean values for 3 or 4 donors     
 
 
 
  
FIG 4 
 
Cytokine bias and in vivo activity of 4′-deoxyphytosphingosine variants                
A) Enhanced plasma membrane lipid raft association of CD1d proteins presenting 4′-deoxyphytosphingosine 
variant AH10-7. Mouse JAWS II dendritic cells were preincubated with glycolipids to allow loading of CD1d 
molecules and then labeled by cell surface binding of fluorochrome conjugated mCD1d/α-GalCer complex-
specific mAb L363. Cells were then treated with 0.05% Triton X-100, and elution of cell surface 
CD1d/glycolipid complexes was monitored over time by flow cytometry. Starting values for MFI were 
normalized to 100%, and the change in MFI values over time are plotted for cells loaded with KRN7000 and the 
other indicated glycolipids. Values at 32.5 seconds post detergent addition (vertical dashed lines) for a minimum 
of four replicate samples were averaged, and the mean ± 1 SE for percent residual MFI is plotted in the bar 
graph on the right. Results shown are representative of three separate experiments. 
B) Serum cytokine levels following systemic injection of glycolipids. Wild type C57BL/6 mice were injected 
i.v. with 4 nmol of each glycolipid or control vehicle (N = 3 mice per group). Serum was collected at 2 and 24 h 
post injection. Mean values ± 1 SE for IFNγ levels at 24 h and IL-4 levels at 2 h are shown (solid bars), and also 
the calculated ratios of these cytokines for each glycolipid (hatched bars). Results shown are representative of 
three separate experiments. 
C) In vivo antitumor activity of glycolipid AH10-7. Wild type C57BL/6 or hCD1d-KI mice were injected 
intravenously with 3 × 105 B16-F10 F10 melanoma cells. Two days later, groups of 11 – 15 mice received i.v. 
injections of KRN7000, AH10-7 (4 nmol) or vehicle. Animals were sacrificed 15 d later, lungs were removed 
and the numbers of tumor nodules were counted visually. Images on the left are representative lungs from wild 
type C57BL/6 (WT) or hCD1d-KI from each of the treatment groups. Graphs on the right show mean values ± 1 
SE for mice treated with vehicle or glycolipids in the WT mice (filled bars) or hCD1d-KI mice (hatched bars). 
This experiment was carried out twice in WT mice, and once in hCD1d-KI mice. 
Asterisks indicate significant differences compared to KRN7000 for A) and B), or for the indicated comparisons 
in C. *P < 0.05, **P < 0.01 ***P < 0.001 and ****P < 0.0001 (ANOVA with Dunnet post-test for multiple 
comparisons).                    
FIG 5 
 
Crystal structures of TCR-mCD1d-glycolipid ternary complexes               
A) Cartoon representations of the 2C12 αβ TCR-mCD1d-AH10-7 (Left panel) and 2C12 αβ TCR-mCD1d-
KRN7000 (Right panel) ternary complexes: mouse CD1d, grey; β2m, light blue; TCR α-chain framework, light 
orange; TCR β-chain framework, pale green; CDR1α, blue; CDR2α, green; CDR3α, red; CDR1β, magenta; 
CDR2β, cyan; CDR3β, orange; AH10-7, black sticks; KRN7000, pale yellow sticks. 
B) Molecular interactions of the 2C12 TCR α- and β-chains with mCD1d. The CDR loops are colored as in 
panel A), and the β-chain framework residues are colored in pale green (structures shown are from the 2C12 αβ 
TCR-mCD1d-AH10-7 complex, and are essentially identical in the KRN7000-containing complex. 
C) Molecular interactions of the 2C12 αβ TCR with the AH10-7 and KRN7000 glycolipid antigens. The AH10-
7 and KRN7000 ligands are shown as sticks and colored in black and pale yellow, respectively. Hydrogen bond 
interactions are shown in magenta dashed lines               
 
 
 
 
  
FIG 6 
 
Affinity and structural basis for iNKT cell TCR binding to C6″-modified variants of KRN7000      
A) Affinity measurements of the 2C12 αβ TCR against mCD1d-AH10-7 and mCD1d-KRN7000. The relative 
binding affinities for each TCR was measured by surface plasmon resonance. Error bars refer to SEM of two 
replicates (n=2). 
B) Superposition of the CD1d/glycolipid complexes from the 2C12 TCR-mCD1d-AH10-7 and 2C12 TCR-
mCD1d-KRN7000 ternary structures. The superposition of both structures is based on the CRα alignment of the 
mCD1d. In the 2C12 TCR-mCD1d-AH10-7 complex, mCD1d (cartoon) and AH10-7 (sticks) are colored in 
black while in the 2C12 TCR-mCD1d-KRN7000, mCD1d and KRN7000 are colored in wheat. 
C) Superposition of the 2C12 TCR-mCD1d-AH10-7, 2C12 TCR-mCD1d-BnNH-GSL and 2C12 TCR-mCD1d-
NU-α-GalCer. For clarity, only mCD1d (light grey) from the 2C12 TCR-mCD1d-AH10-7 ternary complex is 
shown. The lipid-antigens AH10-7, BnNH-GSL-1′ and NU-α-GalCer are colored in black, pale green and light 
blue, respectively.               
 
  
FIG 7 
 
In silico modeling of mCD1d and hCD1d glycolipid complexes in association with iNKT cell TCR          
A-D) QM/MM structures of AH10-7 (red), AH03-1 (green), and KRN7000 (blue). The crystallographic pose of 
AH10-7 is also shown in black in panel A. H-bonding and ion-π stacking interactions are indicated by yellow 
and green dashed lines respectively. Panels A and C correspond to the mCD1d-TCR complexes, while panels B 
and D panels correspond to hCD1d-TCR complexes. 
E) QM/MM binding energies for the KRN7000, AH15-1, AH03-1, AH10-7.           
 
 
  
Table  
 
REAGENT OR SOURCE SOURCE IDENTIFIER 
Antibodies 
L363, anti-mCD1d/αGalCer complex Yu et al., 2007  N/A 
Rat anti-mouse IL-2 (ELISA capture), 
clone JES6-1A12 
BD Biosciences Cat# 554424 
Biotinylated Rat anti-mouse IL-2 (ELISA 
detection), clone JES6-5H4 
BD Biosciences Cat# 554426 
Anti-human IFNγ (ELISA capture), clone 
2G1 
ThermoFisher Scientific Cat# M700A 
Biotinylated anti-human IFNγ (ELISA 
detection), clone B133.5 
ThermoFisher Scientific Cat# M701B 
Anti-human CD3, clone UCHT1 BD Horizon Cat# 563546 
      
Bacterial and Virus Strains 
E. coli BL21 (DE3) Merck Cat# 69450 
      
Biological Samples     
Human peripheral blood mononuclear cells Australian Red Cross Blood 
Service 
Agreement # 13- 04VIC-07 
      
Chemicals, Peptides, and Recombinant Proteins 
KRN7000 glycolipid Avanti, and Dr. G.S. Besra, 
University of Birmingham, 
UK 
h 
AH10-7 glycolipid This paper N/A 
AH03-1 glycolipid Ndonye et al., 2005  N/A 
AH15-1 glycolipid This paper N/A 
DB03-4 glycolipid Dr. G. S. Besra, University 
of Birmingham, UK 
N/A 
PBS-44 glycolipid Dr. P. Savage, Brigham 
Young University, USA 
N/A 
Insect-XPRESS™ Medium Lonza  
Fetal Calf Serum Atlanta Biologicals Cat# S11150 
Triton X-100 Sigma Cat# T8787 
Tween-20 ThermoFisher Cat# BP337-500 
Tyloxapol Sigma Cat# T8761-50G 
Dimethyl sulfoxide (DMSO) Sigma Cat# D8418-100ML 
Recombinant human IL-7 R&D Systems Cat# 207-IL 
Recombinant human IL-2 Peprotech Cat# 200-02 
Recombinant human IFNγ ThermoFisher Scientific Cat# RIFNG50 
Recombinant mouse IL-2 R&D Systems Cat# 402-ML-100 
Recombinant 2C12 NKT TCR This paper N/A 
Recombinant mouse CD1d (mCD1d) This paper N/A 
HisPur™ Ni-NTA affinity resin ThermoFisher Scientific Cat# 88223 
Superdex 200 16/60 size exclusion column GE Healthcare Cat# 28989335 
MonoQ GL anion exchange column GE Healthcare Cat# 17-5166-01 
PEG 3350 Sigma-Aldrich Cat# 202444 
Tacsimate Hampton Research Cat# HR2-825 
Carboxyfluorescein succinimidyl ester 
(CFSE) 
ThermoFisher Scientific Cat# C34554 
Mouse CD1d tetramer, αGalCer-loaded This paper N/A 
      
Critical Commercial Assays 
Mouse CBA Th1/Th2/Th17 Cytokine kit BD Biosciences Cat# 560485 
      
Deposited Data 
Crystal structure 2C12 TCR-CD1d-AH10-
7 
This paper –structure 
deposited 
PDB code: 6BNL 
Crystal structure 2C12 TCR-CD1d-‹-
GalCer 
This paper – structure 
deposited 
PDB code: 6BNK 
Crystal structure mouse CD1d-NU-alpha-
GalCer-iNKT TCR complex 
Aspeslagh et al., 2011  PDB code: 3QUZ 
Crystal structure human NKT TCR-CD1d-
4′deoxy-alpha- galactosylceramide ternary 
complex 
Wun et al., 2012 PDB code: 3VWK 
Crystal structure of CD1d-lipid-antigen 
complexed with Beta-2-Microglobulin, 
NKT15 Alpha-Chain and NKT15 Beta-
Chain 
Borg et al., 2007 PDB code: 2PO6 
Structure of the mouse CD1d-4ClPhC-
alpha-GalCer- iNKT TCR complex 
Aspeslagh et al., 2013  PDB code: 4IRJ 
      
Experimental Models: Cell Lines 
SF9 insect cells ThermoFisher Scientific Cat# 12659017 
HighFive™ insect cells ThermoFisher Scientific Cat# B85502 
DN3A4-1.2 mouse iNKT cell hybridoma Dr. M. Kronenberg N/A 
BW5147α-β-, mouse thymoma line Dr. S. Behar, University of 
Massachusetts, USA 
Letourneur F & Malissen B. 
Eur J Immunol. 1989 
Dec;19(12):2269-74. 
HeLa cells, hCD1d transfected Spada et al., 2000  N/A 
Human iNKT cell clone HDD5 Bricard et al., 2009  N/A 
Human iNKT cell clone HDD3 Bricard et al., 2009  N/A 
B16-F10 mouse melanoma ATCC ATCC CRL-6475 
JAWS II mouse dendritic cell line ATCC ATCC CRL-11904 
      
Experimental Models: Organisms/Strains 
Mouse: C57BL/6 J JAX Stock# 000664 
Mouse: hCD1d-KI (C57BL/6 J 
background) 
Wen et al., 2013 N/A 
      
      
      
      
Oligonucleotides 
      
Recombinant DNA 
2C12 TCR ‹- and ®- chains plasmids in 
pET30 
From Daniel G. Pellicci 
(University of Melbourne) 
N/A 
Mouse CD1d/®2m plasmid Pellicci et al., 2009  N/A 
Software and Algorithms 
Glide Schrodinger Suite 2016-3  
Qsite Schrodinger Suite 2016-3  
Maestro (image rendering) version 
10.6.014 
Schrodinger Suite 2016-3  
iMOSFLM and SCALA Ccp4 suite  
PHASER McCoy et al., 2007   
COOT Emsley et al., 2010   
BUSTER 2.10 Smart et al., 2012  
PYMOL The PyMOL Molecular 
Graphics System, Version 
2.0 Schrödinger, LLC. 
 
BIAevaluation 3.1 Biacore AB  
GraphPad Prism 7.0 GraphPad  
FlowJo, version 10.4 Tree Star, Inc.  
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